DE602005016603D1 - Kristalline formen von (r)-8-chlor-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepinhydrochlorid - Google Patents
Kristalline formen von (r)-8-chlor-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepinhydrochloridInfo
- Publication number
- DE602005016603D1 DE602005016603D1 DE602005016603T DE602005016603T DE602005016603D1 DE 602005016603 D1 DE602005016603 D1 DE 602005016603D1 DE 602005016603 T DE602005016603 T DE 602005016603T DE 602005016603 T DE602005016603 T DE 602005016603T DE 602005016603 D1 DE602005016603 D1 DE 602005016603D1
- Authority
- DE
- Germany
- Prior art keywords
- tetrahydro
- chloro
- methyl
- crystalline forms
- benzazepine hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63822104P | 2004-12-21 | 2004-12-21 | |
PCT/US2005/046983 WO2006069363A2 (en) | 2004-12-21 | 2005-12-20 | Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602005016603D1 true DE602005016603D1 (de) | 2009-10-22 |
Family
ID=36602366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602005016603T Active DE602005016603D1 (de) | 2004-12-21 | 2005-12-20 | Kristalline formen von (r)-8-chlor-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepinhydrochlorid |
Country Status (29)
Country | Link |
---|---|
US (4) | US8168624B2 (de) |
EP (3) | EP2149562A1 (de) |
JP (3) | JP5270167B2 (de) |
KR (1) | KR101281919B1 (de) |
CN (2) | CN101084193B (de) |
AT (1) | ATE442359T1 (de) |
AU (1) | AU2005318959B2 (de) |
BR (1) | BRPI0519726B8 (de) |
CA (1) | CA2589988C (de) |
CU (1) | CU20070138A7 (de) |
CY (1) | CY1109599T1 (de) |
DE (1) | DE602005016603D1 (de) |
DK (1) | DK1838677T3 (de) |
EA (2) | EA017894B1 (de) |
ES (1) | ES2332009T3 (de) |
HK (2) | HK1102812A1 (de) |
HR (1) | HRP20090640T1 (de) |
IL (1) | IL183844A (de) |
MA (1) | MA29147B1 (de) |
ME (1) | ME01090B (de) |
NI (1) | NI200700160A (de) |
NZ (2) | NZ555981A (de) |
PL (1) | PL1838677T3 (de) |
PT (1) | PT1838677E (de) |
RS (1) | RS50996B (de) |
SI (1) | SI1838677T1 (de) |
TN (1) | TNSN07235A1 (de) |
WO (1) | WO2006069363A2 (de) |
ZA (1) | ZA200705125B (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
US8367657B2 (en) * | 2003-06-17 | 2013-02-05 | Arena Pharmaceuticals, Inc. | Processes for preparing 3-benzazepines |
US7704993B2 (en) | 2003-06-17 | 2010-04-27 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
SI1838677T1 (sl) | 2004-12-21 | 2010-01-29 | Arena Pharm Inc | Kristalne oblike (R)-8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin hidroklorida |
BRPI0515862A2 (pt) | 2004-12-23 | 2011-10-11 | Arena Pharm Inc | uso de fentermina e agonista seletivo do receptor de 5ht-2c na preparação de composições, composições moduladoras do receptor de 5ht-2c e forma de dosagem unitária compreendendo as mesmas |
MX2008002180A (es) | 2005-09-01 | 2008-04-22 | Lilly Co Eli | 2,3,4,5-tetrahidro-1h-benzo[d]azepinas 6-sustituidas como agonistas de receptor 5-ht2c. |
WO2007028132A2 (en) | 2005-09-01 | 2007-03-08 | Eli Lilly And Company | 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS |
PL1924560T3 (pl) | 2005-09-01 | 2009-12-31 | Lilly Co Eli | 6 podstawione - 2,3,4,5 - tetrahydro-1h-benzo[d]azepiny jako agoniści receptora 5-ht2c |
CA2619448C (en) | 2005-09-01 | 2013-08-13 | Eli Lilly And Company | 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
EP2001852A2 (de) * | 2006-04-03 | 2008-12-17 | Arena Pharmaceuticals, Inc. | Verfahren zur herstellung von 8-chlor-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepin und entsprechenden zwischenprodukten |
US7897595B2 (en) | 2006-05-26 | 2011-03-01 | Forest Laboratories Holdings Limited | Pyridoazepine derivatives |
EP2099743B1 (de) | 2006-12-05 | 2014-08-27 | Arena Pharmaceuticals, Inc. | Verfahren zur herstellung von (r)-8-chlor-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepin und zwischenprodukten davon |
EP2288585A1 (de) | 2008-03-04 | 2011-03-02 | Arena Pharmaceuticals, Inc. | Verfahren zur herstellung von mit dem 5-ht2c-agonisten (r)-8-chlor-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepin verwandten zwischenprodukten |
US8952197B2 (en) | 2009-06-18 | 2015-02-10 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-HT2C receptor agonists |
WO2011153206A1 (en) | 2010-06-02 | 2011-12-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-ht2c receptor agonists |
IN2013DN02552A (de) * | 2010-09-01 | 2015-08-07 | Arena Pharm Inc | |
CN103189360A (zh) * | 2010-09-01 | 2013-07-03 | 艾尼纳制药公司 | 5-ht2c激动剂的非吸湿性盐 |
CN103189053A (zh) | 2010-09-01 | 2013-07-03 | 艾尼纳制药公司 | 用于体重控制的5-ht2c激动剂的调节释放剂型 |
JP2013540719A (ja) | 2010-09-01 | 2013-11-07 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 腎欠陥を有する個体へのロルカセリンの投与 |
SG188364A1 (en) | 2010-09-01 | 2013-04-30 | Arena Pharm Inc | Salts of lorcaserin with optically active acids |
AU2015268758B2 (en) * | 2010-09-01 | 2017-08-24 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-HT2c agonists useful for weight management |
US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
JP2015534563A (ja) * | 2012-10-09 | 2015-12-03 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 体重管理の方法 |
EP2868656A1 (de) | 2013-11-05 | 2015-05-06 | LEK Pharmaceuticals d.d. | Stabilisiertes amorphes Lorcaserin Hydrochlorid |
WO2015102017A1 (en) * | 2013-11-13 | 2015-07-09 | Cadila Healthcare Limited | Processes for the preparation of lorcaserin |
WO2015096119A1 (zh) * | 2013-12-27 | 2015-07-02 | 杭州普晒医药科技有限公司 | 氯卡色林盐及其晶体、其制备方法和用途 |
EP2924024A3 (de) | 2014-03-21 | 2016-01-20 | Medichem, S.A. | Feste formen von lorcaserinhydrochoride |
US9981912B2 (en) | 2014-04-21 | 2018-05-29 | Hangzhou Pushai Pharmaceutical Technology Co., Ltd. | Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof |
WO2015170346A1 (en) | 2014-05-09 | 2015-11-12 | Council Of Scientific & Industrial Research | A process for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine its enantiomers |
TW201618787A (zh) | 2014-10-30 | 2016-06-01 | 艾尼納製藥公司 | 組合物及方法 |
CN104829532A (zh) * | 2015-05-15 | 2015-08-12 | 浙江理工大学 | 一种制备绿卡色林盐酸盐单晶的方法 |
CN104844512B (zh) * | 2015-05-15 | 2017-03-29 | 东北制药集团股份有限公司 | 一种绿卡色林盐酸盐半水合物晶型的制备方法 |
CA2989885A1 (en) | 2015-06-30 | 2017-01-05 | Neurad Ltd. | Novel breathing control modulating compounds, and methods of making and using same |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
EP3362455A1 (de) | 2015-10-16 | 2018-08-22 | AbbVie Inc. | Verfahren zur herstellung von (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluorethyl)pyrrolidin-1-carboxamid und festkörperformen davon |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
EP3210975A1 (de) | 2016-02-24 | 2017-08-30 | Enantia, S.L. | Cokristalle von lorcaserin |
CN106478506B (zh) * | 2016-09-30 | 2019-03-15 | 山东科兴生物制品有限公司 | 半水绿卡色林盐酸盐的制备方法 |
CN112704670B (zh) * | 2021-01-08 | 2022-07-15 | 安徽中医药大学 | 一种盐酸氯卡色林渗透泵控释制剂及其制备方法 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH498122A (de) | 1968-02-09 | 1970-10-31 | Geigy Ag J R | Verfahren zur Herstellung eines neuen Tetrahydroazepinderivates |
CH481110A (de) | 1967-02-17 | 1969-11-15 | Geigy Ag J R | Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen |
CH500194A (de) | 1968-02-15 | 1970-12-15 | Ciba Geigy Ag | Verfahren zur Herstellung von Tetrahydroazepinderivaten |
US4233217A (en) | 1968-03-11 | 1980-11-11 | Pennwalt Corporation | Substituted 1,2,4,5-tetrahydro-3H, 3 benzazepines |
GB1268243A (en) | 1968-03-11 | 1972-03-22 | Wallace & Tiernan Inc | 0,2,4,5,-tetrahydro-3h,3-benzazepines |
FR7736M (de) | 1968-09-02 | 1970-03-09 | ||
US3716639A (en) | 1970-03-11 | 1973-02-13 | Ciba Geigy Corp | Anorexigenic tetrahydrobenzazepines |
US3795683A (en) | 1970-08-19 | 1974-03-05 | Hoffmann La Roche | 2,3,4,5-tetrahydro-1h-3-benzazepines |
LU65954A1 (de) | 1972-08-25 | 1974-03-07 | ||
US4210749A (en) | 1974-11-12 | 1980-07-01 | Pennwalt Corporation | Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines |
US4111957A (en) | 1977-02-02 | 1978-09-05 | Smithkline Corporation | Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds |
US4108989A (en) | 1977-04-01 | 1978-08-22 | Smithkline Corporation | 2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diones |
CA1090797A (en) | 1978-06-20 | 1980-12-02 | Kenneth G. Holden | Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1h- 3-benzazepine compounds |
AU515236B2 (en) | 1978-06-26 | 1981-03-26 | Smithkline Corporation | Substituted-1-thienyl and furyl-2,3,4,5-tetrahydro-14-3 benzazepine derivatives |
ZA792785B (en) | 1978-07-07 | 1980-08-27 | Smithkline Corp | Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines |
DE3272044D1 (de) | 1981-11-27 | 1986-08-21 | Smithkline Beckman Corp | 3-benzazepines as alpha-2 antagonists |
FR2525603A1 (fr) | 1982-04-27 | 1983-10-28 | Adir | Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique |
US4988690A (en) | 1982-06-14 | 1991-01-29 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines and anti-depressant use thereof |
US4541954A (en) | 1984-09-05 | 1985-09-17 | Smithkline Beckman Corporation | Method for preparing 6-chloro-N-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
US4762845A (en) | 1986-05-21 | 1988-08-09 | Abbott Laboratories | 7-(3-Substituted imino-1-pyrrolidinyl)-quinolone-3-carboxylic acids |
EP0285287A3 (de) | 1987-03-23 | 1990-08-16 | Smithkline Beecham Corporation | Verwendung von 3-Benzazepinen zur Behandlung von gastrointestinalen Mobilitätsstörungen |
PH27337A (en) | 1987-03-27 | 1993-06-08 | Schering Corp | Substituted benzazepines their preparation and pharmaceutical compositions containing them |
US5015639A (en) | 1987-03-27 | 1991-05-14 | Schering Corporation | Substituted benzazepines, their preparation and pharmaceutical compositions containing them |
WO1988007858A1 (en) | 1987-04-09 | 1988-10-20 | Smithkline Beckman Corporation | Sulfinyl and sulfonyl substituted 3-benzazepines |
US5422355A (en) | 1989-06-02 | 1995-06-06 | John Wyeth & Brother, Limited | Composition for treating depression with (N-heteroaryl)alkylamines |
US5178786A (en) | 1989-08-04 | 1993-01-12 | The Lubrizol Corporation | Corrosion-inhibiting compositions and functional fluids containing same |
IL98487A0 (en) | 1990-06-15 | 1992-07-15 | Schering Corp | 8-lower alkyl-5-cycloalkyl or 5-cycloalkenyl substituted benzazepines and pharmaceutical compositions containing them |
US5275915A (en) | 1991-06-05 | 1994-01-04 | Dainippon Ink And Chemicals, Inc. | Developer for light-sensitive material |
PT100602A (pt) | 1991-06-21 | 1993-09-30 | Smithkline Beecham Plc | Uso de derivados de tetra-hidrobenzazepinas, derivados de tetra-hidrobenzazepinas,sua preparacao e composicoes farmaceuticas que os contem |
EP0558824A1 (de) | 1992-02-04 | 1993-09-08 | Duphar International Research B.V | Verfahren zur Herstellung von vicinalen Aminoalkoholen und deren optisch aktive O-geschützte Derivate |
JPH05339263A (ja) | 1992-06-08 | 1993-12-21 | Wakunaga Pharmaceut Co Ltd | ジヒドロピリジン誘導体 |
JPH06298746A (ja) | 1993-04-19 | 1994-10-25 | Showa Denko Kk | 環状イミド酸エステルの製造法 |
CA2166100A1 (en) | 1993-06-23 | 1995-01-05 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
US5387685A (en) | 1993-07-16 | 1995-02-07 | American Cyanamid Co | MDR reversal agents |
GB9322976D0 (en) | 1993-11-08 | 1994-01-05 | Pfizer Ltd | Therapeutic agents |
DE4419247A1 (de) | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Sulfonylierte Pyrrolizincarbonsäureamide und deren Anwendung in der Pharmazie |
DE4419315A1 (de) | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Heteropyrrolizinverbindungen und deren Anwendung in der Pharmazie |
DE4419246A1 (de) | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie |
DE4427838A1 (de) | 1994-08-05 | 1996-02-08 | Thomae Gmbh Dr K | Kondensierte Azepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE4429079A1 (de) | 1994-08-17 | 1996-02-22 | Thomae Gmbh Dr K | Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
JPH08134048A (ja) | 1994-11-08 | 1996-05-28 | Sumitomo Chem Co Ltd | オキサゾリン類の製造法 |
GB9508622D0 (en) | 1995-04-28 | 1995-06-14 | Pfizer Ltd | Therapeutic agants |
JPH0930960A (ja) | 1995-07-18 | 1997-02-04 | Takasago Internatl Corp | 真菌感染症治療剤 |
JPH0987258A (ja) | 1995-09-28 | 1997-03-31 | Sumitomo Chem Co Ltd | オキサゾリン類、その製造方法およびそれを用いる不斉シクロプロパンカルボン酸類の製造方法 |
CA2190708A1 (en) | 1995-12-08 | 1997-06-09 | Johannes Aebi | Aminoalkyl substituted benzo-heterocyclic compounds |
US5892116A (en) | 1996-01-03 | 1999-04-06 | Georgetown University | Gelators |
US5925651A (en) | 1996-04-03 | 1999-07-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5691362A (en) | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
WO1998006701A1 (en) | 1996-08-15 | 1998-02-19 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
AU6290998A (en) | 1997-03-07 | 1998-09-29 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use |
AUPP020297A0 (en) | 1997-11-05 | 1997-11-27 | University Of Melbourne, The | A novel receptor, and compounds which bind thereto |
EP0987235B1 (de) | 1998-08-25 | 2003-03-12 | MERCK PATENT GmbH | Verfahren zur Umsetzung von Arenen oder Alkenen mit Iodalkenen, Aryliodiden oder Arendiazoniumsalzen |
EP1074549B1 (de) | 1999-08-06 | 2003-11-19 | F. Hoffmann-La Roche Ag | Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten |
ES2209728T3 (es) | 1999-08-06 | 2004-07-01 | F. Hoffmann-La Roche Ag | Tetrahidro-benzo(d)azepinas y su uso como antagonistas de receptores de glutamato metabotropico. |
DE10003708A1 (de) | 2000-01-28 | 2001-08-02 | Solvent Innovation Gmbh | Neuartige chirale ionische Flüssigkeiten und Verfahren zu ihrer Darstellung in enantiomerenreiner oder enantiomerenangereicherter Form |
MXPA03004243A (es) | 2000-11-14 | 2004-03-16 | Smithkline Beecham Plc | Derivados de tetrahidrobenzazepina utiles como moduladores de receptores de dopamina d3 (agentes antipsicoticos). |
GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
WO2002074746A1 (fr) | 2001-03-16 | 2002-09-26 | Yamanouchi Pharmaceutical Co., Ltd. | Derives de benzazepine |
DE10119278C1 (de) | 2001-04-20 | 2002-10-02 | Merck Patent Gmbh | Verfahren zur Herstellung von Fluoralkylphosphaten |
US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
AU2002356525A1 (en) | 2001-09-24 | 2003-04-07 | Elan Pharmaceuticals, Inc. | Substituted amines for the treatment of neurological disorders |
JP2005519915A (ja) | 2002-01-18 | 2005-07-07 | セレテック・リミテッド・ライアビリティ・カンパニー | Edg受容体に関連する症状の処置方法 |
CA2478183C (en) | 2002-03-12 | 2010-02-16 | Merck & Co. Inc. | Substituted amides |
US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
US7704993B2 (en) | 2003-06-17 | 2010-04-27 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
US8367657B2 (en) | 2003-06-17 | 2013-02-05 | Arena Pharmaceuticals, Inc. | Processes for preparing 3-benzazepines |
WO2005042491A1 (en) | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
WO2005042490A1 (en) | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
AU2005268781A1 (en) | 2004-08-02 | 2006-02-09 | Genmedica Therapeutics Sl | Compounds for inhibiting copper-containing amine oxidases and uses thereof |
JPWO2006043710A1 (ja) | 2004-10-19 | 2008-05-22 | 株式会社リバース・プロテオミクス研究所 | 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法 |
SI1838677T1 (sl) | 2004-12-21 | 2010-01-29 | Arena Pharm Inc | Kristalne oblike (R)-8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin hidroklorida |
BRPI0515862A2 (pt) | 2004-12-23 | 2011-10-11 | Arena Pharm Inc | uso de fentermina e agonista seletivo do receptor de 5ht-2c na preparação de composições, composições moduladoras do receptor de 5ht-2c e forma de dosagem unitária compreendendo as mesmas |
EP2001852A2 (de) | 2006-04-03 | 2008-12-17 | Arena Pharmaceuticals, Inc. | Verfahren zur herstellung von 8-chlor-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepin und entsprechenden zwischenprodukten |
JP5339263B2 (ja) | 2007-07-26 | 2013-11-13 | コクヨ株式会社 | 引き戸の取付構造、引き戸及び収納装置 |
-
2005
- 2005-12-20 SI SI200530839T patent/SI1838677T1/sl unknown
- 2005-12-20 KR KR1020077016727A patent/KR101281919B1/ko active IP Right Grant
- 2005-12-20 DK DK05855526T patent/DK1838677T3/da active
- 2005-12-20 NZ NZ555981A patent/NZ555981A/en not_active IP Right Cessation
- 2005-12-20 CN CN2005800433929A patent/CN101084193B/zh active Active
- 2005-12-20 EA EA200701358A patent/EA017894B1/ru unknown
- 2005-12-20 PL PL05855526T patent/PL1838677T3/pl unknown
- 2005-12-20 ME MEP-2009-338A patent/ME01090B/me unknown
- 2005-12-20 NZ NZ589756A patent/NZ589756A/en not_active IP Right Cessation
- 2005-12-20 US US11/793,473 patent/US8168624B2/en active Active
- 2005-12-20 CA CA2589988A patent/CA2589988C/en active Active
- 2005-12-20 WO PCT/US2005/046983 patent/WO2006069363A2/en active Application Filing
- 2005-12-20 JP JP2007547060A patent/JP5270167B2/ja active Active
- 2005-12-20 EP EP09011453A patent/EP2149562A1/de not_active Withdrawn
- 2005-12-20 PT PT05855526T patent/PT1838677E/pt unknown
- 2005-12-20 RS RSP-2009/0476A patent/RS50996B/sr unknown
- 2005-12-20 BR BRPI0519726A patent/BRPI0519726B8/pt active IP Right Grant
- 2005-12-20 EA EA201200954A patent/EA201200954A1/ru unknown
- 2005-12-20 AT AT05855526T patent/ATE442359T1/de active
- 2005-12-20 ES ES05855526T patent/ES2332009T3/es active Active
- 2005-12-20 EP EP05855526A patent/EP1838677B1/de active Active
- 2005-12-20 EP EP10010048.6A patent/EP2327698B1/de active Active
- 2005-12-20 CN CN2011103046342A patent/CN102321023A/zh active Pending
- 2005-12-20 DE DE602005016603T patent/DE602005016603D1/de active Active
- 2005-12-20 AU AU2005318959A patent/AU2005318959B2/en active Active
-
2007
- 2007-06-11 IL IL183844A patent/IL183844A/en active IP Right Grant
- 2007-06-15 CU CU20070138A patent/CU20070138A7/es unknown
- 2007-06-20 TN TNP2007000235A patent/TNSN07235A1/fr unknown
- 2007-06-20 ZA ZA2007/05125A patent/ZA200705125B/en unknown
- 2007-06-21 NI NI200700160A patent/NI200700160A/es unknown
- 2007-07-12 MA MA30070A patent/MA29147B1/fr unknown
- 2007-10-16 HK HK07111117.8A patent/HK1102812A1/xx unknown
-
2009
- 2009-11-10 CY CY20091101162T patent/CY1109599T1/el unknown
- 2009-12-02 HR HR20090640T patent/HRP20090640T1/hr unknown
-
2011
- 2011-10-27 HK HK11111630.0A patent/HK1157334A1/xx unknown
-
2012
- 2012-03-21 US US13/425,669 patent/US8697686B2/en active Active
- 2012-05-18 JP JP2012114460A patent/JP5781008B2/ja active Active
- 2012-09-14 US US13/616,887 patent/US8980881B2/en active Active
-
2014
- 2014-06-02 JP JP2014113743A patent/JP2014156490A/ja active Pending
-
2015
- 2015-03-02 US US14/635,146 patent/US20160009654A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE442359T1 (de) | Kristalline formen von (r)-8-chlor-1-methyl-2,3,4,5-tetrahydro-1h-3-be zazepinhydrochlorid | |
HUS2100028I1 (hu) | ERBB I. típusú receptor tirozinkináz-gátló N4-fenil-kinazolin-4-amin származékok és rokon vegyületeik a hiperproliferatív betegségek kezelésére | |
NO20065178L (no) | Tienopyridinderivater | |
BRPI0519597A2 (pt) | derivados de (3r, 6r)-3-(2, 3-diidro-1h-inden-2-il)-2, 5-piperazinadiona 1, 6-substituÍda como antagonistas de receptores de oxitocina para o tratamento de parto prematuro, dismenorrÉia e endometriose | |
WO2006099468A3 (en) | Process for the purification of duloxetine hydrochloride | |
DE602004024798D1 (de) | Herstellung von quetiapin | |
ATE398121T1 (de) | Neue synthese von irbesartan | |
IL183700A0 (en) | Process for production of (4,5-dihydroisoxazol-3-yl)thio-carboxamidine salts | |
ZA200700447B (en) | Method for producing (Z)-1-phenyl-1-diethylaminocarbonyl-2-aminomethyl | |
NO20050885D0 (no) | Ny fremgangsmate for syntesen av 1,3-dihydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre | |
WO2005087770A3 (de) | 5, 6-dihydrocarbyl-7-amino-triazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen sowie sie enthaltende mittel | |
AU2002367268A1 (en) | Processes for production of cyclic diamine compounds or salts thereof | |
DE602006003204D1 (de) | Reinigungsverfahren von Moxonidine | |
HUP0400767A2 (hu) | Javított eljárás tiszta ondansetron-hidroklorid-dihidrát előállítására | |
DE602005012365D1 (de) | Verfahren zur synthese von n-ä3-(3-cyanopyrazoloä1,5aüpyrimidin-7-yl)-phenylü-n-ethylacetamid | |
TW200407314A (en) | Preparation of 4, 6-dichloro-5-fluoropyrimidine | |
DE602004014237D1 (de) | Herstellungsverfahren von kristallinem Losartan-Kaliumsalz |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |